By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Roche 

340 Kingsland Street

Nutley  New Jersey  07110  U.S.A.
Phone: 973-235-5000 Fax: 973-235-7605


SEARCH JOBS
For more than 100 years, Roche has built a legacy of innovation, decade by decade, discovery by discovery. We continue to focus on developing new, innovative and clinically differentiated medicines in five key areas: central nervous system, inflammation, metabolism, oncology, and virology.

To maintain our innovative focus, the 127-acre site in New Jersey has expanded its research base to become one of the largest R&D centers for Roche. Nutley is the center for research in Oncology, Inflammation and Virology. These areas have a rich pipeline comprised of novel first-in-class and best-in-class compounds and have at their disposal the expertise of scientists in Discovery Technologies.

Cancer - Scientists are employing innovative molecular biology tools that will allow identification and validation of the critical targets for cancer drug discovery and diagnostic development. Using an integrated approach, we aim to combine specific anti-cancer drugs with diagnostic tests, thereby improving the treatment of cancer by selecting suitable patients and monitoring the progress of therapy. The overall goal is to make cancer therapy more personalized, safer and more effective, thus reducing overall cancer morbidity and mortality. Roche leads the industry in late stage oncology trials. With a broad portfolio of tumor markers for prostate, colorectal, liver, ovarian, breast, stomach, pancreatic and lung cancer, as well as a range of molecular oncology tests, Roche will continue to be a leader in providing cancer-focuses treatments and diagnostics.

Inflammation - Inflammatory diseases affect millions of people around the globe, leading to pain, disability, disfigurement and in some cases, death. In this area, we seek ways to uncover new approaches to treating a range of diseases including severe asthma, chronic obstructive pulmonary disease (COPD) and rheumatoid arthritis. Our vision is to become the leader in inflammation by shaping future treatment and rebuilding patients' lives. Roche ranks second in the industry with inflammation clinical trials.

Virology - Inflammatory diseases affect millions of people around the globe, leading to pain, disability, disfigurement and in some cases, death. In this area, we seek ways to uncover new approaches to treating a range of diseases including severe asthma, chronic obstructive pulmonary disease (COPD) and rheumatoid arthritis. Our vision is to become the leader in inflammation by shaping future treatment and rebuilding patients' lives. Roche ranks second in the industry with inflammation clinical trials.

Discovery Technologies - Scientists in this group have expertise in a number of areas including protein cloning and expression, cell line development, microbial fermentation and cell culture production, protein purification, biochemical and cell-based assay development, high throughput screening, monoclonal antibody development, automation technology, compound profiling and high content screening. Their efforts support research in oncology, inflammation virology.


Key Statistics


Email:
Ownership: Public

Web Site: Roche
Employees:
Symbol: RHHBY
 



Industry
Big Pharma


Collaborations

IDEC Pharmaceuticals, Inc. 

Millennium: The Takeda Oncology Company  Obesity and Type II Diabetes, Agreement signed in March 1994, $50 Million plus milestone payments

ProScript 

Incyte Corporation 

Human Genome Sciences, Inc.  Anti-Microbial Gene Partnerships

CuraGen Corporation (Acquired by Celldex Therapeutics, Inc.)  Product Discovery, Pharmacogenomics, and Diagnostics





Company News
For Roche (RHHBY) CEO, Celebrating Failure Is Key To Success 9/17/2014 6:57:14 AM
Roche (RHHBY) To Invest $535M, Create 3,500 Jobs At New Swiss IT Site 9/17/2014 6:37:12 AM
BioHealth Innovation Signs Agreement With Roche (RHHBY) To Source Technologies For Research, Development And Commercialization 9/15/2014 9:01:10 AM
Roche (RHHBY) Again Ranked Most Sustainable Healthcare Company In The Dow Jones Sustainability Indices 9/11/2014 10:22:14 AM
Roche (RHHBY) To Slash 100 Jobs In Response To Price Controls 9/3/2014 6:13:13 AM
Disappointment Looms As Roche (RHHBY) Drops Plans To Bid For The Rest Of Chugai Pharmaceutical Co., Ltd. (Japan) 8/26/2014 6:00:53 AM
Spring BioScience, a subsidiary of Ventana Medical Launches Highly Sensitive PD-L1 (SP142) Antibody, A Component Of Roche (RHHBY)'s Immunotherapy Assay 8/25/2014 9:02:45 AM
How Roche (RHHBY) And Pfizer Inc. (PFE) Are On Different M&A Paths 8/25/2014 6:21:40 AM
Roche (RHHBY) Pays $8.3 Billion For Bay Area's InterMune, Inc. (ITMN), Pledges To Keep Employees 8/24/2014 7:38:32 PM
Roche (RHHBY) May Gobble Up The Rest Of Chugai Pharmaceutical Co., Ltd. (Japan) For $10 Billion 8/15/2014 10:51:33 AM
12345678910...
//-->